Albireo to Report First Quarter 2021 Financial Results on May 6
Albireo Pharma (Nasdaq: ALBO) has announced a conference call and webcast scheduled for May 6, 2021, at 10:00 a.m. ET, to discuss the company's first-quarter financial results. The call will provide a business update, focusing on its lead product candidate, odevixibat, currently in Phase 3 trials for rare pediatric liver diseases, including PFIC and Alagille syndrome. The company aims for FDA Priority Review with a PDUFA goal date set for July 20, 2021. Albireo is also advancing a Phase 1 trial for A3907 targeting adult cholestatic liver disease.
- FDA Priority Review for odevixibat with PDUFA goal date of July 20, 2021.
- Phase 3 trials for odevixibat in PFIC and Alagille syndrome ongoing.
- Initiated Phase 1 clinical trial for A3907 targeting adult cholestatic liver disease.
- None.
Conference call and webcast to be held at 10:00 a.m. ET
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on May 6, 2021, to provide a business update and review the company’s financial results for the first quarter ended March 31, 2021.
To access the live conference call by phone, please dial 888-599-8686 (domestic) or 323-994-2082 (international) and provide the access code 8407763. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, https://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 trials in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA granted Priority Review and set a PDUFA goal date of July 20, 2021. In Europe, the EMA validated MAA.Odevixibat is the only IBATi granted accelerated assessment by the EMA. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What is the date of Albireo Pharma's conference call?
What will be discussed in the upcoming Albireo Pharma conference call?
What is the significance of the FDA Priority Review for Albireo?
What are the current clinical trials Albireo Pharma is conducting?
